Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Mecapegfilgrastim in Neoadjuvant Biliary Tract Carcinoma
NCT06037655Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in biliary tract carcinoma (BTC), sponsored by Jiangsu Provincial People's Hospital. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT06037655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037655.